Mutations in mitochondrial aminoacyl-tRNA synthetases are an increasingly recognized cause of human diseases, often arising in individuals with compound heterozygous mutations and presenting with system-specific phenotypes, frequently neurologic. FARS2 encodes mitochondrial phenylalanyl transfer ribonucleic acid (RNA) synthetase (mtPheRS), perturbations of which have been reported in 6 cases of an infantile, lethal disease with refractory epilepsy and progressive myoclonus. Here the authors report the case of juvenile onset refractory epilepsy and progressive myoclonus with compound heterozygous FARS2 mutations. The authors describe the clinical course over 6 years of care at their institution and diagnostic studies including electroencephalogram (EEG), brain magnetic resonance imaging (MRI), serum and cerebrospinal fluid analyses, skeletal muscle biopsy histology, and autopsy gross and histologic findings, which include features shared with Alpers-Huttenlocher syndrome, Leigh syndrome, and a previously published case of FARS2 mutation associated infantile onset disease. The authors also present structure-guided analysis of the relevant mutations based on published mitochondrial phenylalanyl transfer RNA synthetase and related protein crystal structures as well as biochemical analysis of the corresponding recombinant mutant proteins.
Defects in nuclear genes encoding mitochondrial aminoacyl-tRNA synthetases are increasingly linked to a variety of pediatric and adult onset disorders, 1 many with relative selectivity of organ systems affected, particularly the central nervous system. [2] [3] [4] [5] [6] The mechanism by which perturbations of aminoacyl-tRNA synthetases produce clinical phenotypes remains unclear, but is generally thought to involve a defect in mitochondrial translation, defects in other effects of which have been linked to other human diseases with similar phenotypes. 7 FARS2 (encoding mitochondrial phenylalanyl transfer ribonucleic acid [RNA] synthetase) is the nuclear encoded aminoacyl-tRNA synthetase required for the charging of the cognate mitochondrial tRNA with phenylalanine. Defects in this enzyme would presumably impact the expression of the 13 mitochondrially encoded peptides, including subunits of the mitochondrial respiratory chain. 8 To date, 6 individuals with FARS2 mutations (3 siblings with homozygous missense mutations, 9 2 siblings with compound heterozygous missense mutations, 10 and 1 infant with a missense mutation and a large deletion) 11 have been reported, all presenting with a clinical phenotype of infantile onset refractory epilepsy and myoclonus (Table 1) . [9] [10] [11] In all cases there was a characteristic, relative specificity of the phenotype to the central nervous system, all but 1 were deceased by age 3-24 months at the time of reporting. Of the 3 with MRI findings reported, all had abnormalities ranging from isolated white matter abnormalities 11 to cortical atrophy with putaminal signal abnormalities, 10 and subdural fluid collections. 9 Decreased COX staining was reported in 2 patients, 9, 10 but no ragged red fibers were observed in either of 2 patients with reported muscle biopsy. 10, 11 Serum lactate elevations were reported in 3 cases. 10, 11 In the sole individual for whom autopsy information was available, an Alpers-Huttenlocher-like features were reported including brain weight <30% of normal, generalized atrophy, gliosis, and subtotal laminar necrosis of the entire cortical ribbon. 10 The missense mutations reported in compound heterozygote and homozygote patients were all highly conserved in eukaryotic but not prokaryotic PheRS. One missense mutation from compound heterozygote patients is located at the adenosine triphosphate (ATP) binding site while the other lies at an interdomain interface. The missense mutation of the homozygous patients maps to a distinct interdomain interface. 10 Recombinant mutant proteins for each of the missense mutations demonstrated decreased or mildly decreased catalytic efficiency and more severely impacted refolding compared to wild type in vitro. 10 Here, the authors report a case of a young woman with novel compound heterozygous FARS2 mutations and a central nervous system-specific phenotype of childhood onset refractory epilepsy, progressive myoclonus with features in some brain regions reminiscent of Alpers-Huttenlocher syndrome and a previously published case of FARS2 mutation associated infantile onset disease 10 as well as a region with findings similar to Leigh syndrome in addition to characterization of enzyme kinetics and apparent binding affinities of recombinant, mutant mitochondrial phenylalanyl transfer ribonucleic acid (RNA) synthetase (mtPheRs) proteins.
Materials and Methods

Bioinformatics and Structure-Guided Analysis
Multiple sequence alignments were performed using CLC Sequence Viewer Version 6.8.2 (CLC Bio, Qiagen, Portland, Oregon, USA). Crystal structures were reviewed and graphics created using Pymol. 12 
Functional Assays
Protein expression and purification. E. coli Rosetta (DE3) cells containing pRARE plasmids encoding tRNAs for rare codons were transformed with either wild type (WT) plasmid pET21c-PheRS (a gift from L. Spremulli, University of North Carolina, Chapel Hill, NC, USA) or mutant mtPheRS plasmids P85A and H135D. Point mutations were introduced by site directed mutagenesis using the Quick-Change protocol (Stratagene). Cultures were grown at 37 C to OD ¼ 0.8 and induced with 0.5 mM Isopropyl b-D-1-thiogalactopyranoside (IPTG) for 4 h. Cells were harvested, sonicated and supernatant was collected after centrifugation at 25 000xg for 1 h. The supernatant was applied to a TALON metal affinity resin column (Clontech), followed by washing and the protein was eluted with 25 mM Tris-HCl, pH 8.0, 300 mM NaCl, 250 mM imidazole and 10% glycerol. Fractions containing mtPheRS were checked for electrophoretic purity by SDS-PAGE, pooled and dialyzed overnight at 4 C in 50 mM Tris-HCl, pH 7.5, 5 mM MgCl 2 and 100 mM KCl. The purified enzyme was concentrated, adjusted to 50% (v/v) glycerol and aliquots were stored at -80 C. E. coli tRNA Phe was made by T7 runoff transcription as previously described. 10, 13 DNA template for tRNA transcription was generated from plasmids carrying tRNA genes by polymerase chain reaction (PCR) amplification. The tRNA was phenol chloroform extracted and purified on a diethylaminoethyl (DEAE) sepharose column, as described previously. 10, 13 In vitro tRNA aminoacylation. Endpoint in vitro aminoacylation was performed at 37 C in aminoacylation buffer [100mMNa-Hepes (pH 7.2), 30mMKCl, 2 mM ATP, and 10 mM MgCl 2 ] containing 40 mM L-[ 14 C]Phe (174 cpm pmolÀ1; Perkin-Elmer Lifesciences), 5 mM E. coli tRNA Phe transcript, and 100 nM mtPheRS. 8 ml aliquots were removed and spotted on 3MM filter disks (Whatman), washed 3 times in 10% trichloroacetic acid, once with 95% ethanol, and then dried. The amount of radioactivity retained was determined by liquid scintillation counting. Steady state kinetics for tRNA Phe were determined at 37 C as described previously with concentrations of in vitro transcribed E. coli tRNA Phe varying between 0.1 and 5 mM and enzyme added to a final concentration of 100 nM. 13 ATP-PPi exchange. Adenosine triphosphate-pyrophosphate (ATP-PPi) exchange rate for amino acid activation was determined according to standard methods as previously described. 13 Reactions were carried out at 37 C in a medium containing 100 mM Na-Hepes (pH 7.2), 30 mM KCl, 10 mM MgCl 2 , 2 mM NaF, 2 mM ATP, 2 mM [ 32 P]PPi (2 cpm/pmol), Phe (15 mM), and 50 nM mtPheRS. After 1-5 min, 25 ml of the reaction were removed and added to a solution containing 1% charcoal, 5.6% HClO4, and 75 mM PPi. The charcoal-bound ATP was filtered through a 3 MM Whatman filter discs under vacuum and washed 3 times with 5 ml of water and once with 5 ml of ethanol. The filters were dried, and the radioactivity content was determined by liquid scintillation counting.
Thermostability assay. To assay protein stability, active fractions of 5 mM of all the protein samples were incubated at 37 C. Enzyme activity was monitored by active-site titration and was performed in 50-mL reaction mixtures containing 100 mM Na-Hepes (pH 7.2), 30 mM KCl, 10 mM MgCl 2 , 2 mM ATP, 40 mM L-[ 14 C]Phe (174 cpm pmolÀ1). Pyrophosphatase was also added to ensure a unidirectional formation of aminoacyl adenylate. The reaction was initiated by the addition of mtPheRS to a reaction mixture preincubated at 37 C for 5 min. After addition of the enzyme, the reaction was performed for 10 min at 37 C and then filtered through a nitrocellulose membrane (PROTRAN BA85; Whatman) prewashed with cold 0.5Â aminoacylation buffer. The filters were then washed with 3 mL of cold 0.5Â aminoacylation buffer and dried at 80 C for 15 min. The amount of radioactivity retained was quantified by liquid scintillation counting.
Patient Studies
Transient elevations of serum lactate were noted as high as 6.4 mmol/ L (normal range 0.5-2.2 mmol/L). Muscle biopsy included examination of skeletal muscle of the right thigh using hematoxylin and eosin stain, modified Gomori's trichrome, reduced nicotinamide adenine dinucleotide (NADH) reductase, oil red O, PAS, COX/SDH, and adenosine triphosphatase (ATPase) (at pH 4.3, 4.6, and 9.4) stains as well as electron microscopy by standard methods. Microscopic analysis of formalin-fixed brain tissue was performed using hematoxylin, eosin, and luxol blue stains per standard methods.
Spectrophotometeric analysis of oxidative phosphorylation, skin fibroblast pyruvate dehydrogenase and pyruvate carboxylase activity, and butyrobetaine levels were performed at the Center for Inherited Disorders of Energy Metabolism (Case Western Reserve University). Assessment of mitochondrial DNA content of skeletal muscle was performed by qPCR analysis at Baylor University.
Results
Genetic Findings
Dual genome panel by massively parallel sequencing (Baylor College of Medicine -MitomeNGS) revealed 3 nuclear variants of unknown significance and 2 mitochondrial variants of unknown significance. Nuclear variants included 2 mutations in FARS2: c.253C>G (p.P85A, exon 2) and c.403C>G (p.H135D, exon2) as well as a single missense mutation in the pyruvate carboxylase gene PC, c.2786C>G (p.A929G, exon 20). The PC variant was predicted to be benign due to only moderate evolutionary conservation of Alanine-929 and inconsistency with the above reported clinical phenotype. A whole exome sequencing study was also performed (GeneDx, Gaithersburg, MD) that confirmed the 2 variants in the FARS2 gene, and demonstrated compound heterozygosity, with 1 allele inherited from each parent. No other significant findings were found by whole exome sequencing.
Bioinformatics and Structure-Guided Analysis
To better understand potential biologic implications of the FARS2 mutations identified, bioinformatics and crystal structure-guided analysis were undertaken. Multiple sequence alignments of orthologous enzymes from mouse, chicken, amphibian, insect, yeast, and bacterial species were performed and reveal that the residues affected by the missense mutations are highly conserved through evolution, including in Escherichia coli (Figure 1) . Notably, the mutations identified each convert the amino acid in question to a residue with distinct biochemical properties. Proline-85, the residue with the most restrictive main chain conformations, is mutated to an alanine with both a greater number of potential main chain conformations and a more positive hydropathy score. 14 Likewise, histidine-135 is mutated to an aspartate, producing a complete charge reversal of the side chain. Review of the published crystal structure of the mtPheRS-Phe-AMP complex 15 identifies proline-85 as a buried residue while the side chain of histidine-135 is exposed. Both residues lie within the larger ''catalytic domain,'' though neither contacts the Phe-AMP moiety within the active site (Figures 2a, 4b ). Proline-85 constitutes the N-terminal most residue of the ''Motif 1'' alpha helix that, interestingly, is required for oligomerization of class II aminoacyl-tRNA synthetases and is speculated to perform other functions as well, though its significance in mtPheRs, which functions as a monomer is unclear. Histidine-135 forms part of an alpha helix within the region connecting Motif 1 and Motif 2, the second of 3 highly conserved structural elements common to class II aaRSs. In the crystal structure of the orthologous protein T. thermophilus-PheRS-bound to tRNA Phe , this conserved intermotif region forms 1 of 2 catalytic domain loops that associate with the acceptor stem of the tRNA molecule 16 (Figure 2c ). Of note, the T. thermophilus enzyme is a class II enzyme that like class I enzymes charges the 2'OH group (as opposed to the 3'-OH group) of the terminal tRNA ribose and is composed of 2 alpha-beta subunit heterodimers, in contrast to human mtPheRs which is monomeric but shares significant sequence homology with the alpha subunit of T. thermophilus PheRS.
Functional Assays
To assess the impact of the identified P85A and H135D substitutions on enzyme function, the authors expressed and purified recombinant mutant mtPheRS proteins in E. coli per established protocols. 13 End point aminoacylation reactions indicated that P85A mtPheRS charges tRNA very similarly to WT, but H135D demonstrated severe aminoacylation deficiency ( Figure  3) . Determination of the steady-state kinetics for tRNA revealed that mutant P85A has a 2-fold increase in catalytic efficiency when compared to WT, while kinetic parameters for H135D were unable to be determined using standard techniques, reinforcing the previously observed aminoacylation deficiency (Figure 3) .
To better understand the cause of this aminoacylation deficiency, the authors performed end-point pyrophosphate exchange experiments. At a phenylalanine concentration of 15 mM, twice the reported K M for human mtPheRS, mutant P85A is unable to produce a measurable amount of activity, suggesting that the K m of P85A for Phenylalanine is higher than the reported WT value. H135D mtPheRS showed a moderate amount of activity, suggesting that the observed aminoacylation deficiency is likely due to a defect in tRNA binding and not amino acid activation (Figure 3 ).
The stability of WT and mutant proteins was assessed by active site titration after incubation at either room temperature or 37 C. At room temperature, neither mutation has a measurable impact on protein stability. However, when tested at 37 C, mutant P85A appears to have decreased stability when compared to WT (Figures 3a, 3b ).
Clinical Phenotype
The patient was the second child of healthy, nonconsanguineous parents born without complication at 38 weeks gestation via normal spontaneous vaginal delivery. The pregnancy was complicated by gestational diabetes; the perinatal period was unremarkable. She was noted to have no major dysmorphic features. As an infant she was noted to have both motor and speech delays, first walking independently at 17 months, running at 24 months, and requiring a gait belt for safe ambulation End point aminoacylation reactions indicated that mutant P85A mtPheRS charges tRNA very similarly to WT, but H135D demonstrated severe aminoacylation deficiency. Determination of the steady-state kinetics for tRNA revealed that mutant P85A has a 2-fold increase in catalytic efficiency when compared to WT, while kinetic parameters for H135D were unable to be determined using standard techniques, reinforcing the previously observed aminoacylation deficiency. End-point pyrophosphate exchange experiments were also performed. At a phenylalanine concentration of 15 mM, twice the reported Km for human mtPheRS, mutant P85A is unable to produce a measurable amount of activity, suggesting that the Km of P85A for phenylalanine is higher than the reported WT value. Mutant H135D mtPheRS showed a moderate amount of activity, suggesting that the observed aminoacylation deficiency is likely due to a defect in tRNA binding and not amino acid activation. The stability of WT and mutant proteins was assessed by active site titration after incubation at either room temperature or 37 C. At room temperature, neither mutation has a measurable impact on protein stability. However, when tested at 37 C, mutant P85A appears to have decreased stability when compared to WT.
at 5 years of age. Fine motor delays were likewise noted through school age. She spoke her first word at age 3.5 years. Her parents reported that her language skills plateaued at age 5-7 years at which point she was speaking in 3-to 4-word sentences with frequent grammatical errors. Paucity of speech and marked word retrieval difficulties were noted at age 9 years, at which time her neurologic exam revealed no focal findings beyond the aforementioned developmental delays. Her first seizure, a prolonged generalized tonic-clonic convulsion, occurred at 8 years of age at which time antiepileptic therapy was initiated. Electroencephalogram (EEG) at age 9 years revealed mild background slowing in full wakefulness, as well as frequent epileptiform discharges without clinical correlate, including 3.0-3.5 Hertz (Hz) spike and slow wave discharges with bifrontal predominance, frequent runs of semirhythmic generalized 3 Hz slowing maximal over the left frontal region, and frequent runs of irregular sharp-slow wave activity, predominantly occurring over the right posterior quadrant. These discharges increased in frequency with sleep, occupying 65-70% of her sleep record. This initially responded to high-dose (1 mg/kg) diazepam with significant improvement of her EEG and some improvement in her speech and motor skills. Her EEG, however, again worsened with increasingly frequent bursts of generalized 3-4 Hz spike and wave activity in wakefulness and increasingly frequent generalized spikes in sleep. Her epilepsy both evolved and progressed, despite management with multiple antiepileptic medications (including valproate, with no resultant liver dysfunction) with focal seizures and epilepsia partialis continua occurring with increased frequency starting at 10 years of age. At age 13, she developed status epilepticus and progressed to have multiple subsequent events of status epilepticus that proved refractory to standard medical management, 2 experimental medical trials, the ketogenic diet, and corpus callostomy. This progression of her epilepsy was accompanied by the development and progressive worsening of nonepileptic myoclonus. Notably, the corpus callostomy was complicated by subdural fluid collection requiring external ventricular drain placement. MRI brain at that time revealed extensive areas of abnormal T2 hyperintensity in the frontal lobes (right greater than left), anterior cingulate gyri, left superior frontal gyrus, bilateral temporal lobes, and left cerebellar cortex in the setting of recent seizure. Magnetic resonance spectroscopy in the left basal ganglia region demonstrated an unremarkable metabolic spectrum. Repeat multivoxel magnetic resonance spectroscopy of the bilateral cerebral hemispheres 1 year later also showed normal metabolite ratios.
Despite a notable absence of disease process in any other organ or system, her neurologic status progressively deteriorated throughout this time. She had a mild decline in skills from ages 9-10 after an initial improvement following diazepam administration, and further decline with her convulsive seizures beginning at age 10. The patient's neurological status precipitously declined after the onset of her initial episode of status epilepticus at age 13 and, 10 days prior to death at the age of 15 years, her neurologic exam was notable for inability follow commands or track faces, bilaterally unreactive pupils, nearcontinuous myoclonus of the right face, arm, and leg, absence of purposeful movement, and up-going toes bilaterally. Repeat MRI brain performed 2 months prior to death demonstrated the presence of the known fluid collection as well as T2 hyperintensity within the left caudate and left medial temporal lobe, and the right medial occipital lobe along the superior bank of the right calcarine sulcus with encephalomalacia of the calcaravis (Figure 4 ). EEG performed weeks prior to death revealed generalized, irregular theta and delta background slowing and near-continuous bihemispheric independent and synchronous . Magnetic resonance imaging (MRI) brain. MRI brain performed at age 15 years, 2 months prior to death revealing T2 hyperintensity within the left caudate and left medial temporal lobe, and the right medial occipital lobe along the superior bank of the right calcarine sulcus with encephalomalacia of the calcaravis. Notably, earlier corpus callostomy for refractory seizures was complicated by the right subdural fluid collection also seen in this image, requiring external ventricular drain placement. epileptiform discharges over the frontotemporal regions with shifting side predominance, at times corresponding to myoclonus, but more often not synchronous with the clinical myoclonus. She was hospitalized with likely pneumonia and urinary tract infections and died after being found apneic with pulseless arrest. An autopsy was performed.
Enzymatic, Histological, and Autopsy Findings
Skeletal muscle biopsy was obtained at age 14 years and notable for predominantly type 2 fiber atrophy with rounded, atrophic fibers scattered throughout with rare regenerative fibers but without type grouping on hematoxylin-eosin stain, ATPase PH 4.3, 4.6, and 9.4 stains. There was no evidence of inflammation or myonecrosis. NADH staining showed targetoid fibers. Gomoritrichome, PAS, and oil red O stains demonstrated normal patterns of staining. Combined COX/SDH stain was unremarkable. Electron microscopy revealed fibers with focal myofibrillary disarray, many myelin figures, abundant enlarged and swollen mitochondria containing glycogen and no inclusions (Supplemental Figure 1) .
Polargraphic analysis of oxidative phosphorylation performed at the Center for Inherited Disorders of Energy Metabolism (Case Western Reserve University) demonstrated normal activity of Complexes I-IV (frozen specimen).
Mitochondrial DNA content of skeletal muscle (qPCR analysis, performed at Baylor University) was reported at 61% of control (within normal). Normal pyruvate dehydrogenase, pyruvate carboxylase activity was noted in skin fibroblasts. ''Markedly decreased'' butyrobetaine, suggestive of a defect in carnitine biosynthesis was noted in the same specimen but these findings are likely attributable to the patient's therapeutic ketogenic diet.
Autopsy gross specimens revealed a normal sized heart, enlarged liver (1960gm, normal 1500-1800gm), superficial hemorrhagic necrosis of the colon, and a small brain (830 g, normal 1250-1400 g; 1.4% total body weight (TBW). Microscopic analysis of brain and spinal cord revealed a diffuse, predominantly cortical, as well as subcortical process characterized by laminar cortical neuron loss and gliosis, diminished subcortical white matter and descending corticospinal tracts. The most severely affected regions included the bilateral frontorbital cortices and the bilateral primary visual cortices. In frontorbital cortex there was almost complete absence of neurons, excessive gliosis, pale white matter, and fragmenting of the cortical layers. The primary visual cortex is notable for a devastated line of Genari, almost complete absence of neurons, excessive gliosis, pale white matter, and fragmenting of the cortical layers extending through cortical layer 5. Notably, a large autopsy series of 32 patients with Alpers-Huttenlocher syndrome (a progressive degenerative encephalopathy related to polymerase gamma mutations) has previously reported characteristic findings of macroscopic cortical thinning, microscopic spongiosis with neuronal loss and astrocytosis that is most severe in the occipital lobe. 17, 18 Similar findings were also reported in an infant with FARS2 mutations and progressive myoclonus epilepsy. 10 In addition, a small region of spongiform change was noted in the right thalamus ( Figure 5 ) which was reminiscent of the spongiform lesions with relative 
Discussion
Here, the authors report a case of compound heterozygous FARS2 mutations in association with childhood onset refractory epilepsy, progressive myoclonus, cortical necrosis similar that seen on autopsy in Alpers-Huttenlocher syndrome as well as a previously reported case of FARS2 mutation-associated infantile onset disease, and limited basal ganglia spongiform findings similar to those observed in Leigh syndrome. The authors also present bioinformatics and biochemical data to support a causal link. The clinical course, neuroimaging, and neuropathological findings 10 the authors report are strikingly similar to cases described in association with distinct FARS2 mutations in 2 previous publications, 9, 10 with the exception of age of onset, supporting a genetic association while suggesting an attenuated phenotype in this case. Together, these data support a distinct neuropathologic process related to perturbations of mtPheRS function. This report underscores the phenotypic variability associated with FARS2 mutations and highlights the utility of genetic testing in cases of severe, refractory epilepsy and developmental delay. The data presented here provide a plausible explanation for pathogenicity of the FARS2 mutations observed. Taken together, the kinetic assays support a deficiency in the activation of amino acid for P85A, and a deficiency in the transfer of activated amino acid to tRNA for H135D mtPheRS. In addition, P85A mtPheRS proteins demonstrated decreased stability at body temperature. Because proline-85 is buried and surrounded by 5 aromatic residues within a 5 Å radius (histidine-48, tyrosine-288, phenylalanine-296, phenylalanine-303, and phenylalanine-307), it is conceivable that perturbation of this residue might impact the stability of tertiary structural elements. Regarding the H135D substitution, review of the tRNA Phe bound T. thermophilus PheRS structure reveals that the sidechain hydroxyl group of tyronsine-267 lies within 3.5 Å of a histidine-135 nitrogen, creating the possibility of a weak electrostatic interaction that might influence the tertiary structure of 2 loops that surround the acceptor stem of the tRNA. Disruption of such an interaction by charge reversal at the 135 position could potentially interfere with the binding of the acceptor stem, a possibility supported by experiments with recombinant mutant proteins. Presumably, these defects are each less potent than those observed in previously published cases.
Two features of interest are raised by this case. This case represents compound heterozygous mutations of a mitochondrial aminoacyl-tRNA synthetase, which has been seen in a preponderance of reports linking mitochondrial aminoacyl-tRNA synthetase mutations and clinical phenotypes, perhaps due to a frequently embryonic lethal homozygous phenotype in the case of most mitochondrial aminoacyl-tRNA synthetase mutations. 1 In addition, despite variation in severity of clinical presentation and duration of illness (presumably sufficient to impact other organ systems), the apparent nervous system-specificity of published phenotypes associated with FARS2 perturbations is preserved. Similar tissue or organ system specificities have been noted with genetic perturbation of other mitochondrial aminoacyl-tRNA synthetase. [2] [3] [4] [5] [6] It remains to be determined whether this is a result of a relative but differential impact on the expression of specific mitochondrially encoded peptides or the crossing of a threshold of generalized organelle dysfunction to which a given tissue-particularly nervous system tissuesmight be more sensitive. Further work is required to more precisely delineate the pathogenic mechanisms underlying mutations in mitochondrial aminoacyl-tRNA synthetase proteins as well as all diseases affecting mitochondrial translation.
